Joel Portice Named New Intermedix Chief Executive Officer
Fort Lauderdale, Fla. (PRWEB) February 11, 2015 -- Intermedix Corporation, a leader in technology-enabled health and safety solutions, announced Wednesday that Joel Portice will succeed Doug Shamon as the company’s new chief executive officer.
Portice brings to Intermedix more than 20 years of experience in the government, business and health care industries. He was the co-founder and former chief operating officer of Enclarity and most recently served as division president of government solutions and corporate strategy at HMS Holdings Corp.
“The Intermedix team has built a strong and innovative enterprise with market leadership and operations in the U.S. and around the world,” said Portice. “It is both an honor and a privilege to lead the company in the next phase of its growth and lifecycle.”
Intermedix co-founder Doug Shamon, who has held the position of president and CEO since the company’s inception, will continue to be involved in corporate strategy as chairman of the board of directors.
“The future is bright for Intermedix,” said Shamon. “I am confident that with Joel’s fresh perspective, Intermedix will continue to be an innovative leader and provide world-class solutions to support global health and safety.”
Portice was selected as CEO by the Intermedix board of directors following an extensive national search.
Intermedix is majority owned by Thomas H. Lee Partners, one of the world’s oldest and most experienced private equity firms.
About Intermedix
Intermedix delivers technology-enabled professional services to health care providers, government agencies and corporations. The company supports approximately 15,000 health care providers with comprehensive business and revenue cycle management services and connects more than 95 percent of the U.S. population and customers in 16 countries around the world with crisis management and emergency preparedness and response technologies. For more information, visit h http://www.intermedix.com.
Lisa Jardim, Intermedix Corporation, http://www.intermedix.com, +1 (954) 334-6672, [email protected]
Share this article